BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peters HP, Laarakkers CM, Wetzels JF, Swinkels DW. Hepcidin levels in patients with renal disease. Kidney Int. 2009;76:680; author reply 680-681. [PMID: 19721430 DOI: 10.1038/ki.2009.238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 Ashby DR, Gale DP, Busbridge M, Maxwell PH, Choi P. Response to ‘Hepcidin levels in patients with renal disease’. Kidney International 2009;76:680-1. [DOI: 10.1038/ki.2009.240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages. Eur J Pharmacol 2021;912:174583. [PMID: 34678238 DOI: 10.1016/j.ejphar.2021.174583] [Reference Citation Analysis]
3 Troutt JS, Butterfield AM, Konrad RJ. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J Clin Lab Anal 2013;27:504-10. [PMID: 24218134 DOI: 10.1002/jcla.21634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
4 Hsieh YP, Huang CH, Lee CY, Chen HL, Lin CY, Chang CC. Hepcidin-25 negatively predicts left ventricular mass index in chronic kidney disease patients. World J Nephrol 2013; 2(2): 38-43 [PMID: 24175264 DOI: 10.5527/wjn.v2.i2.38] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]